Core Viewpoint - The new controlling shareholder Xu Xiren has completed a management reshuffle at Peking University Pharmaceutical, but the company faces significant operational challenges and potential revenue loss due to the termination of key contracts with its largest client, Peking University International Hospital [2][5][6]. Group 1: Management Changes - After taking control, Xu Xiren appointed himself as CEO and made significant changes to the management team, including the resignation of long-standing executives [3][12]. - The previous management team, which had successfully turned around the company's performance, has largely departed, raising concerns about continuity and stability [12][14]. Group 2: Operational Challenges - Peking University Pharmaceutical is experiencing disruptions due to historical issues related to employee benefits, leading to protests from retired staff that have affected administrative operations [5]. - The company has relied heavily on its relationship with Peking University International Hospital, which accounted for approximately 78% of its drug distribution revenue in 2024 [15][16]. Group 3: Financial Implications - The termination of the contract with Peking University International Hospital, which was valued at 12 billion yuan over three years, poses a risk of losing approximately 910 million yuan in annual sales and 36.66 million yuan in net profit starting in 2025 [19][22]. - Despite the termination, the company had previously indicated a potential future collaboration worth 40.5 million yuan, but this has been contradicted by recent statements confirming the end of all cooperation [20][22].

Group 1 - The new actual controller of Beijing University Pharmaceutical, Xu Xiren, has completed a management reshuffle within eight months of taking control [1][2][6] - The company has faced operational disruptions due to historical issues related to retirement benefits and housing, affecting its administrative order [3][7] - The termination of cooperation with Peking University International Hospital, which was the company's largest client, poses a significant challenge to revenue stability [3][9] Group 2 - Xu Xiren acquired control of Beijing University Pharmaceutical at a symbolic price of 1 yuan, gaining control over a company valued at nearly 4 billion yuan [5][6] - The management changes initiated by Xu Xiren have led to the departure of key executives, including the former president who had significantly improved the company's performance [6][7] - The company’s revenue from pharmaceutical distribution was 1.437 billion yuan in 2024, with a substantial portion linked to Peking University International Hospital [7][8] Group 3 - A long-term service contract worth 1.2 billion yuan per year with Peking University International Hospital is set to expire in April 2025, raising concerns about future revenue [8][9] - If the company fails to win the upcoming tender for the hospital's procurement needs, it could face a revenue drop of approximately 910 million yuan and a net profit loss of about 36.66 million yuan starting in 2025 [9]